GotzschePC, HrobjartssonA, MaricK, TendalB.Data extraction errors in meta-analyses that use standardized mean differences. JAMA2007;298:430–7.
2.
KhanderiaU, Pop-BusuiR, EagleKA. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother2008;42:1466–74. Epub 12 Aug 2008. DOI 10.1345/aph.1K666
3.
HomePD, PocockSJ, Beck-NielsenH. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med2007;357:28–38.
4.
GersteinHC, MillerME, ByingtonRP. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;358:2545–59.
5.
PatelA, MacMahonS, ChalmersJ. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:2560–72.
6.
DuckworthWC, AbrairaC, MoritzT.Veterans Affairs Diabetes Trial American Diabetes Association 68th Scientific Sessions San Francisco, 2008.
7.
BARI 2D Study Group.Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am Heart J 2008;156:528–36.e5.
8.
NathanDM, BuseJB, DavidsonMB. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2008;31:173–5.
9.
OhkuboY, KishikawaH, ArakiE. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract1995;28:103–17.
10.
UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352:837–53.
11.
KahnSE, HaffnerSM, HeiseMA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med2006;355:2427–43.
12.
HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008;359:1577–89.
